Drug name: Oxaliplatin + Cyclopamine
Oxaliplatin
| Cas.no | PubChem ID |
| 61825-94-3 | 6857599 |
| Known Target | |
| DNA | |
| Structure | |
 |
|
| Introduction | |
| Oxaliplatin undergoes nonenzymatic conversion to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and transcription. Cytotoxicity is cell-cycle nonspecific. | |
Cyclopamine
| Cas.no | PubChem ID |
| 4449-51-8 | 442972 |
| Known Target | |
| Smoothened homolog | Q99835 |
| Structure | |
 |
|
| Introduction | |
| Cyclopamine is naturally occuring steroidal alkaloid that causes cyclopia by blocking sonic hedgehog signaling. Cyclopamine is currently being investigated as a treatment agent in basal cell carcinoma, medulloblastoma, and rhabdomyosarcoma, tumors that result from excessive Hh activity, glioblastoma, and as a treatment agent for multiple myeloma. It is currently under phase I of clinical trial. | |
Reference
- [1] Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. Song, Z., et al. (2011).PLoS One. 6(3):e17687.
21394208. [ 21394208 ]